Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1U01AI068636 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the effectiveness and safety of an antiretroviral therapy (ART) regimen consisting of raltegravir (RAL) and darunavir (DRV)/ritonavir (RTV) as first-line therapy in treatment-naïve participants.
Despite the remarkable strides made in the treatment of HIV-1-infected persons over the last decade, current first-line ART regimens are imperfect. The ideal combination, unlike some current first-line options, would have uncompromised efficacy in the presence of transmitted drug-resistant variants. The primary purpose of this study is to estimate the cumulative proportion of ART-naive participants experiencing virologic failure at or prior to week 24 after initiating raltegravir (RAL) plus darunavir/ritonavir (DRV/RTV).
The study will last 52 weeks. All participants will follow the same treatment schedule and take RAL plus DRV/RTV orally daily for the duration of the trial.
After entry, all participants will have scheduled visits at weeks 1, 4, 12, 24, 36, 48, and 52. Medical/medication history, blood and urine collection, and liver function tests will occur at screening. A targeted physical exam and concomitant medications history will occur at all study visits. Blood and urine collection and liver function tests will occur at most study visits. For females, a pregnancy test will occur at screening and study entry.
RAL and DRV were provided by the study. RTV was not provided by the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RAL + DRV/RTV | Experimental | Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Raltegravir | Drug | 400 mg tablet taken orally twice daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants With Virologic Failure After Initiating RAL Plus DRV/RTV at or Prior to Week 24 | Virologic failure is defined as: at week 12, confirmed plasma HIV-1 RNA >= 1000 copies/ml or confirmed rebound from the week 4 value by >0.5 log10 copies/ml (for subjects with week 4 value <= 50 copies/ml, confirmed rebound to >50 copies/ml); at week 24 or later, confirmed value > 50 copies/ml. Viral load confirmation was scheduled 7-35 days after initial virologic failure. The proportion was estimated using Kaplan-Meier method. An adaptation of Greenwood's variance estimate was used in constructing the confidence interval. | From start of study treatment to week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants With Virologic Failure or Off Study Treatment Regimen or Death at or Prior to Week 24 | The proportion of participants with virologic failure (see primary outcome measure for definition) and/or premature treatment discontinuation/modification and/or death was estimated using Kaplan-Meier method. An adaptation of Greenwood's variance estimate was used in constructing the confidence interval. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joseph J. Eron, Jr., MD | University of North Carolina, Chapel Hill | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AlabamaTherapeutics CRS | Birmingham | Alabama | 35294 | United States | ||
| Stanford CRS |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19155770 | Background | Capetti AF, Piconi S, Landonio S, Rizzardini G, Perno CF. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):233-4. doi: 10.1097/QAI.0b013e31818c7e8e. No abstract available. | |
| 19149996 | Background | Long MC, King JR, Acosta EP. Pharmacologic aspects of new antiretroviral drugs. Curr HIV/AIDS Rep. 2009 Feb;6(1):43-50. doi: 10.1007/s11904-009-0007-y. |
Not provided
Not provided
Study participants were HIV-1-infected, antiretroviral(ARV)-naive men and women, 18 years and older with plasma HIV-1 RNA >= 5000 copies/ml. One enrolled participant never started study treatment.
Study participants were recruited from 22 U.S. sites from April 2009 to August 2009.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | RAL + DRV/RTV | Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Darunavir/Ritonavir | Drug | 800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily |
|
|
| From start of study treatment to Week 24 |
| Change in Plasma HIV-1 RNA From Baseline to Week 1 | Results report the week 1 change from baseline (week 1 - baseline) in HIV-1 RNA. Baseline HIV-1 RNA was computed as the mean of the log10 HIV-1 RNA values at pre-entry and study entry. | Baseline and week 1 |
| Proportion of Participants With Plasma HIV-1 RNA < 50 Copies/ml or <200 Copies/ml at Week 24 | Results report the percentage of participants with plasma HIV-1 RNA < 50 copies/ml or <200 copies/ml at week 24. | From start of study treatment to week 24 |
| Proportion of Participants With Plasma HIV-1 RNA <50 Copies/ml or <200 Copies/ml at Week 48 | Results report the percentage of participants with plasma HIV-1 RNA <50 copies/ml or <200 copies/ml at week 48. | From start of study treatment to week 48 |
| Proportion of Participants Who Experienced Signs/Symptoms or Laboratory Toxicities Grade 3 or Higher, or of Any Grade Which Led to a Permanent Change or Discontinuation of Study Treatment | Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Results report the percentage of participants who had grade 3 or higher events, or events of any grade which led to a permanent change or discontinuation of study treatment, which occurred any time from start of treatment to end of treatment. | From start of study treatment to week 52 |
| Number of Participants With Pretreatment Drug Resistance | Results report the number of participants who had resistance to non-nucleoside reverse transciptase inhibitors (NNRTI), nucleoside reverse transciptase inhibitors (NRTI) and protease inbitors (PI) based on genotypic resistance testing done prior to participant's entry into the study. Participants are classified into one (and only one category) based on the maximum number of drug class resistance seen for the participant. | At screening |
| Number of Participants With Integrase Drug Resistance at Virologic Failure | Results report the number of participants who had integrase resistance mutation(s) detected at the time of virologic failure. | From 12 weeks after starting study treatment to week 52 |
| Number of Participants With Protease Drug Resistance at Virologic Failure | Results report the number of participants who had protease resistance mutation(s) detected at the time of virologic failure. | From 12 weeks after starting study treatment to week 52 |
| Number of Participants With Perfect Overall Adherence by Self Report | At each study visit, adherence was measured in terms of the number of missed doses each participant had over a 4-day recall for each drug. Adherence for all study visit weeks were combined for an overall measure of adherence. Participants who had zero missed doses on all weeks in all drugs while on study were classified as having an overall "perfect" adherence. | From one week after starting study treatment to week 52 |
| Changes in Fasting Total Cholesterol, High-density Lipoprotein and Triglyceride at Week 24 | Results report the week 24 change from week 0 (week 24 - week 0) fasting total cholesterol, high-density lipoprotein and triglyceride. | From start of study treatment through week 24 |
| Change in Fasting Low-density Lipoprotein at Week 24 | Results report the week 24 change from week 0 (week 24 - week 0) fasting low-density lipoprotein (LDL). For participants whose calculated fasting LDL and direct fasting LDL were both reported, only the calculated fasting LDL was used. Direct fasting LDL was reported when the participant had high fasting triglyceride. | From start of study treatment through week 24 |
| Changes in Fasting Total Cholesterol, High-density Lipoprotein and Triglyceride at Week 48 | Results report the week 48 change from week 0 (week 48 - week 0) fasting total cholesterol, high-density lipoprotein and triglyceride. | From start of study treatment through week 48 |
| Change in Fasting Low-density Lipoprotein at Week 48 | Results report the week 48 change from week 0 (week 48 - week 0) fasting low-density lipoprotein (LDL). For participants whose calculated fasting LDL and direct fasting LDL were both reported, only the calculated fasting LDL was used. Direct fasting LDL was reported when the participant had high fasting triglyceride. | From start of study treatment through week 48 |
| Change in CD4 Count at Week 48 | Results report the week 48 change from baseline (week 48 - baseline) in CD4 count. Baseline CD4 count was computed as the mean of CD4 count values at pre-entry and study entry. | From start of study treatment through week 48 |
| Plasma Trough Concentration of Raltegravir | Plasma trough concentrations (ng/ml) of Raltegravir (RAL) below the detection limit (10 ng/ml) were replaced by half the corresponding lower limit of quantitation. Geometric mean of trough concentrations obtained within the prescribed trough time (within 9-15 hours after the last RAL dose) was computed for each participant. For participants who experienced virologic failure (see primary outcome measure definition), only those concentrations on or before virologic failure confirmation were used in the geometric mean computation. | From start of study treatment to week 52 |
| Plasma Trough Concentration of Darunavir | Plasma trough concentrations (ng/ml) of Darunavir (DRV) below the detection limit (50 ng/ml) were replaced by half the corresponding lower limit of quantitation. Geometric mean of trough concentrations obtained within the prescribed trough time (within 20-28 hours after the last DRV dose) was computed for each participant. For participants who experienced virologic failure (see primary outcome measure definition), only those concentrations on or before virologic failure confirmation were used in the geometric mean computation. | From start of study treatment to week 52 |
| Palo Alto |
| California |
| 94304 |
| United States |
| Ucsd, Avrc Crs | San Diego | California | 92103 | United States |
| Ucsf Aids Crs | San Francisco | California | 94110 | United States |
| University of Colorado Hospital CRS | Aurora | Colorado | 80045 | United States |
| Georgetown University CRS | Washington D.C. | District of Columbia | 20007 | United States |
| Northwestern University CRS | Chicago | Illinois | 60611 | United States |
| Beth Israel Deaconess Med Center | Boston | Massachusetts | 02115 | United States |
| Brigham and Women's Hosp. ACTG CRS | Boston | Massachusetts | 02115 | United States |
| Washington U CRS | St Louis | Missouri | 63110 | United States |
| AIDS Community Health Ctr. ACTG CRS | Rochester | New York | 14604 | United States |
| Unc Aids Crs | Chapel Hill | North Carolina | 27599 | United States |
| Duke Univ. Med. Ctr. Adult CRS | Durham | North Carolina | 27710 | United States |
| Univ. of Cincinnati CRS | Cincinnati | Ohio | 45267-0405 | United States |
| Case CRS | Cleveland | Ohio | 44106 | United States |
| MetroHealth CRS | Cleveland | Ohio | 44109 | United States |
| The Ohio State Univ. AIDS CRS | Columbus | Ohio | 43210 | United States |
| Hosp. of the Univ. of Pennsylvania CRS | Philadelphia | Pennsylvania | 19104 | United States |
| University of Pittsburgh CTU | Pittsburgh | Pennsylvania | 15213 | United States |
| The Miriam Hospital | Providence | Rhode Island | 02906 | United States |
| Vanderbilt Therapeutics CRS | Nashville | Tennessee | 37203 | United States |
| Houston AIDS Research Team | Houston | Texas | 77030 | United States |
| 19131522 | Background | Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos. 2009 Apr;37(4):809-20. doi: 10.1124/dmd.108.024109. Epub 2009 Jan 8. |
| 21857490 | Derived | Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ Jr; ACTG A5262 Team. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011 Nov 13;25(17):2113-22. doi: 10.1097/QAD.0b013e32834bbaa9. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | RAL+DRV/RTV | Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Age (in years) of participants at study entry | Median | Full Range | years |
| |||||||||||||||||||||
| Age, Customized | Age (in years) of participants at study entry | Number | participants |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Participants With Virologic Failure After Initiating RAL Plus DRV/RTV at or Prior to Week 24 | Virologic failure is defined as: at week 12, confirmed plasma HIV-1 RNA >= 1000 copies/ml or confirmed rebound from the week 4 value by >0.5 log10 copies/ml (for subjects with week 4 value <= 50 copies/ml, confirmed rebound to >50 copies/ml); at week 24 or later, confirmed value > 50 copies/ml. Viral load confirmation was scheduled 7-35 days after initial virologic failure. The proportion was estimated using Kaplan-Meier method. An adaptation of Greenwood's variance estimate was used in constructing the confidence interval. | All participants who started study treatment were included. The intent-to-treat approach was used, ignoring whether a participant was on or off treatment at the time of HIV-1 RNA measurement and censoring follow-up if a participant was lost-to-follow-up without previously meeting the definition of virologic failure. | Posted | Number | 95% Confidence Interval | Proportion of participants | From start of study treatment to week 24 |
|
|
| |||||||||||||||||||||||||
| Secondary | Proportion of Participants With Virologic Failure or Off Study Treatment Regimen or Death at or Prior to Week 24 | The proportion of participants with virologic failure (see primary outcome measure for definition) and/or premature treatment discontinuation/modification and/or death was estimated using Kaplan-Meier method. An adaptation of Greenwood's variance estimate was used in constructing the confidence interval. | All participants who started study treatment were included in the analysis. | Posted | Number | 95% Confidence Interval | Proportion of participants | From start of study treatment to Week 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Change in Plasma HIV-1 RNA From Baseline to Week 1 | Results report the week 1 change from baseline (week 1 - baseline) in HIV-1 RNA. Baseline HIV-1 RNA was computed as the mean of the log10 HIV-1 RNA values at pre-entry and study entry. | Analyis was based on an intent-to-treat approach, ignoring whether a participant was on or off study treatment at the time the sample for HIV-1 RNA was obtained. | Posted | Median | Inter-Quartile Range | log10 copies/ml | Baseline and week 1 |
|
| ||||||||||||||||||||||||||
| Secondary | Proportion of Participants With Plasma HIV-1 RNA < 50 Copies/ml or <200 Copies/ml at Week 24 | Results report the percentage of participants with plasma HIV-1 RNA < 50 copies/ml or <200 copies/ml at week 24. | All participants who started study treatment were included. An intent-to-treat approach was used ignoring participants who were off-study or with missing HIV-1 RNA at week 24. | Posted | Number | 95% Confidence Interval | proportion of participants | From start of study treatment to week 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Proportion of Participants With Plasma HIV-1 RNA <50 Copies/ml or <200 Copies/ml at Week 48 | Results report the percentage of participants with plasma HIV-1 RNA <50 copies/ml or <200 copies/ml at week 48. | All participants who started study treatment were included. An intent-to-treat approach was used ignoring participants who were off study treatment or with missing HIV-1 RNA at week 48. | Posted | Number | 95% Confidence Interval | proportion of participants | From start of study treatment to week 48 |
|
| ||||||||||||||||||||||||||
| Secondary | Proportion of Participants Who Experienced Signs/Symptoms or Laboratory Toxicities Grade 3 or Higher, or of Any Grade Which Led to a Permanent Change or Discontinuation of Study Treatment | Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Results report the percentage of participants who had grade 3 or higher events, or events of any grade which led to a permanent change or discontinuation of study treatment, which occurred any time from start of treatment to end of treatment. | All participants who started study treatment were included in the analysis. | Posted | Number | 95% Confidence Interval | proportion of participants | From start of study treatment to week 52 |
|
| ||||||||||||||||||||||||||
| Secondary | Number of Participants With Pretreatment Drug Resistance | Results report the number of participants who had resistance to non-nucleoside reverse transciptase inhibitors (NNRTI), nucleoside reverse transciptase inhibitors (NRTI) and protease inbitors (PI) based on genotypic resistance testing done prior to participant's entry into the study. Participants are classified into one (and only one category) based on the maximum number of drug class resistance seen for the participant. | All participants who started study treatment were included in the analysis. | Posted | Number | participants | At screening |
|
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Integrase Drug Resistance at Virologic Failure | Results report the number of participants who had integrase resistance mutation(s) detected at the time of virologic failure. | Only those participants who had virologic failure (see primary outcome measure for definition) and who had successful integrase genotyping at failure were included in the analysis. | Posted | Number | participants | From 12 weeks after starting study treatment to week 52 |
|
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Protease Drug Resistance at Virologic Failure | Results report the number of participants who had protease resistance mutation(s) detected at the time of virologic failure. | Only those participants who had virologic failure (see primary outcome measure for definition) and who had successful protease genotyping at failure were included in the analysis. | Posted | Number | participants | From 12 weeks after starting study treatment to week 52 |
|
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Perfect Overall Adherence by Self Report | At each study visit, adherence was measured in terms of the number of missed doses each participant had over a 4-day recall for each drug. Adherence for all study visit weeks were combined for an overall measure of adherence. Participants who had zero missed doses on all weeks in all drugs while on study were classified as having an overall "perfect" adherence. | All participants who started study treatment were included in the analysis. | Posted | Number | participants | From one week after starting study treatment to week 52 |
|
| |||||||||||||||||||||||||||
| Secondary | Changes in Fasting Total Cholesterol, High-density Lipoprotein and Triglyceride at Week 24 | Results report the week 24 change from week 0 (week 24 - week 0) fasting total cholesterol, high-density lipoprotein and triglyceride. | Only those participants who started study treatment and who had fasting lipid measurements at week 24 and week 0 were included in the analysis. | Posted | Median | Inter-Quartile Range | mg/dL | From start of study treatment through week 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Change in Fasting Low-density Lipoprotein at Week 24 | Results report the week 24 change from week 0 (week 24 - week 0) fasting low-density lipoprotein (LDL). For participants whose calculated fasting LDL and direct fasting LDL were both reported, only the calculated fasting LDL was used. Direct fasting LDL was reported when the participant had high fasting triglyceride. | Only those participants who started study treatment and who had fasting lipid measurements at week 24 and week 0 were included in the analysis. | Posted | Median | Inter-Quartile Range | mg/dL | From start of study treatment through week 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Changes in Fasting Total Cholesterol, High-density Lipoprotein and Triglyceride at Week 48 | Results report the week 48 change from week 0 (week 48 - week 0) fasting total cholesterol, high-density lipoprotein and triglyceride. | Only those participants who started study treatment and who had fasting lipid measurements at week 48 and week 0 were included in the analysis. | Posted | Median | Inter-Quartile Range | mg/dL | From start of study treatment through week 48 |
|
| ||||||||||||||||||||||||||
| Secondary | Change in Fasting Low-density Lipoprotein at Week 48 | Results report the week 48 change from week 0 (week 48 - week 0) fasting low-density lipoprotein (LDL). For participants whose calculated fasting LDL and direct fasting LDL were both reported, only the calculated fasting LDL was used. Direct fasting LDL was reported when the participant had high fasting triglyceride. | Only those participants who started study treatment and who had fasting lipid measurements at week 48 and week 0 were included in the analysis. | Posted | Median | Inter-Quartile Range | mg/dL | From start of study treatment through week 48 |
|
| ||||||||||||||||||||||||||
| Secondary | Change in CD4 Count at Week 48 | Results report the week 48 change from baseline (week 48 - baseline) in CD4 count. Baseline CD4 count was computed as the mean of CD4 count values at pre-entry and study entry. | Only those participants who started study treatment and who have values at baseline and at week 48 were included in the analysis. | Posted | Median | Inter-Quartile Range | cells/mm3 | From start of study treatment through week 48 |
|
| ||||||||||||||||||||||||||
| Secondary | Plasma Trough Concentration of Raltegravir | Plasma trough concentrations (ng/ml) of Raltegravir (RAL) below the detection limit (10 ng/ml) were replaced by half the corresponding lower limit of quantitation. Geometric mean of trough concentrations obtained within the prescribed trough time (within 9-15 hours after the last RAL dose) was computed for each participant. For participants who experienced virologic failure (see primary outcome measure definition), only those concentrations on or before virologic failure confirmation were used in the geometric mean computation. | Participants who started study treatment and who have at least one RAL plasma trough concentration obtained within 9-15 hours after the last RAL dose were included in the analysis. | Posted | Median | Inter-Quartile Range | ng/ml | From start of study treatment to week 52 |
|
| ||||||||||||||||||||||||||
| Secondary | Plasma Trough Concentration of Darunavir | Plasma trough concentrations (ng/ml) of Darunavir (DRV) below the detection limit (50 ng/ml) were replaced by half the corresponding lower limit of quantitation. Geometric mean of trough concentrations obtained within the prescribed trough time (within 20-28 hours after the last DRV dose) was computed for each participant. For participants who experienced virologic failure (see primary outcome measure definition), only those concentrations on or before virologic failure confirmation were used in the geometric mean computation. | Participants who started study treatment and who have at least one DRV plasma trough concentration obtained within 20-28 hours after the last DRV dose were included in the analysis. | Posted | Median | Inter-Quartile Range | ng/ml | From start of study treatment to week 52 |
|
|
From start of study treatment to week 52
Expedited adverse event (AE) reporting followed Intensive Division of AIDS (DAIDS) Reporting Level, which included AEs resulting in death, congenital anomalies, fetal losses, significant disabilities, requiring hospitalization, and >=grade 3 AEs defined by the "DAIDS Table for Grading the Severity of Adult and Pediatric AEs", V1.0, 12/2004.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | RAL+DRV/RTV | Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks | 13 | 112 | 78 | 112 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Jejunal perforation | Gastrointestinal disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Injection site reaction | General disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA 13.1 | Systematic Assessment |
| |
| Perirectal abscess | Infections and infestations | MedDRA 13.1 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 13.1 | Systematic Assessment |
| |
| Alcohol poisoning | Injury, poisoning and procedural complications | MedDRA 13.1 | Systematic Assessment |
| |
| Diabetes mellitus | Metabolism and nutrition disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Convulsion | Nervous system disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Substance abuse | Psychiatric disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Suicide attempt | Psychiatric disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Renal failure acute | Renal and urinary disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Henoch-Schonlein purpura | Skin and subcutaneous tissue disorders | MedDRA 13.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA 14.0 | Systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| Aspartate aminotransferase increased | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| Blood cholesterol | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| Blood glucose abnormal | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| Blood sodium decreased | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| Blood uric acid increased | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| Low density lipoprotein abnormal | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| Neutrophil count decreased | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| White blood cell count decreased | Investigations | MedDRA 14.0 | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 14.0 | Systematic Assessment |
|
This is a single-arm study.
In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| ACTG ClinicalTrials.gov Coordinator | ACTG Network Coordinating Center, Social and Scientific Systems, Inc. | (301) 628-3313 | ACTGCT.Gov@s-3.com |
| ID | Term |
|---|---|
| D000068898 | Raltegravir Potassium |
| D000069454 | Darunavir |
| D019438 | Ritonavir |
| ID | Term |
|---|---|
| D011760 | Pyrrolidinones |
| D011759 | Pyrrolidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D002219 | Carbamates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D005663 | Furans |
| D013844 | Thiazoles |
| D001393 | Azoles |
Not provided
Not provided
| 40-49 |
|
| 50-59 |
|
| 60-69 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|